Julien Rongère

Dr. Rongère joined AC Immune S.A. in July 2017 as Head of European Regulatory Affairs and Quality Assurance. Prior to AC Immune, Dr.Rongère held positions of increasing responsibility at Celgene in Switzerland. Most recently, he served as Director, Regulatory Affairs, leading the development of regulatory strategies for small molecules and CAR-T cell therapies and contributed to the development and approval of Revlimid in Multiple Myeloma and Mantle Cell Lymphoma. Prior to Celgene, he served as a Regulatory Expert at Apoxis, S.A. in Switzerland. During his career, Dr.Rongère gained specific expertise in the development of regulatory strategies for taking products from Phase 1 through to commercialization in the field of hematology/oncology and immunology/inflammation, including fast to market approaches, orphan drugs and pediatric development. Dr.Rongère gained his Masters Degree in Medical Genetics from the University of Aberdeen, UK, and holds a PhD in Molecular Biology from the University of Lausanne, Switzerland.